Low-grade inflammation in type 2 diabetes: a cross-sectional study from a Danish diabetes outpatient clinic

Objectives To investigate low-grade inflammation in type 2 diabetes and explore associations to clinical aspects as well as microvascular and macrovascular complications. Design Cross-sectional analysis. Setting The outpatient diabetes clinic at the Department of Endocrinology at Aalborg University Hospital, Denmark. Participants 100 participants with type 2 diabetes confirmed by a haemoglobin A1c (HbA1c)≥6.5% for a minimum of 1 year and 21 healthy controls. Outcome measures Serum levels of 27 inflammation-related biomarkers measured by immunoassay. Associations with microvascular and macrovascular complications, body weight, glycaemic control, medication and sex were investigated in the diabetes cohort. Results Serum levels of tumour necrosis factor (TNF)-α and eotaxin were elevated in type 2 diabetes (p<0.05), while interleukin (IL)-7 was decreased (p<0.001). IL-12/IL-23p40, IL-15, macrophage-derived chemokine (MDC) and C reactive protein (CRP) levels were increased with body weight (p<0.05), while eotaxin and TNF-α were increased with elevated HbA1c levels (p<0.04). Dipeptidyl peptidase-4 inhibitor therapy was associated with lower levels of induced protein-10, MDC and thymus and activation regulated chemokine (p<0.02), while females had higher levels of MDC (p=0.027). Individuals with ≥3 diabetic complications had elevated levels of IL-6, IL-10, IL-12/IL-23p40, IL-15 and CRP compared with those with ≤3 (p<0.05). Conclusion The level of low-grade inflammation in type 2 diabetes is associated with obesity, glycaemic regulation, therapeutical management, sex and complications. Our results underline the importance of addressing inflammatory issues in type 2 diabetes, as these may predispose for crippling comorbidities.

[1]  E. Roselló-Lletí,et al.  Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models , 2022, International journal of molecular sciences.

[2]  T. He,et al.  Liraglutide improves pancreatic islet β cell apoptosis in rats with type 2 diabetes mellitus by inhibiting the IKKε/NF-κB pathway. , 2021, European review for medical and pharmacological sciences.

[3]  Xiao-ming Meng,et al.  Epigenetics and Inflammation in Diabetic Nephropathy , 2021, Frontiers in Physiology.

[4]  J. Weaver,et al.  MiR-126, IL-7, CXCR1/2 receptors, inflammation and circulating endothelial progenitor cells: The study on targets for treatment pathways in a model of subclinical cardiovascular disease (type 1 diabetes mellitus) , 2021, Journal of Translational Medicine.

[5]  A. Lambiase,et al.  Diabetic retinopathy, oxidative stress and sirtuins: an in depth look in enzymatic patterns and new therapeutic horizons. , 2021, Survey of ophthalmology.

[6]  J. Halcox,et al.  Glucagon‐like peptide‐1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta‐analysis of randomised controlled trials , 2021, Diabetes, obesity & metabolism.

[7]  K. Node,et al.  Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial , 2020, Diabetes, metabolic syndrome and obesity : targets and therapy.

[8]  A. Drewes,et al.  Cardiac vagal tone as a novel screening tool to recognize asymptomatic cardiovascular autonomic neuropathy: Aspects of utility in type 1 diabetes. , 2020, Diabetes research and clinical practice.

[9]  Sai Zhang,et al.  Glucagon-like peptide-1 receptor agonist Exendin-4 improves neurological outcomes by attenuating TBI- induced inflammatory responses and MAPK activation in rats. , 2020, International immunopharmacology.

[10]  R. Xavier,et al.  Sex-Specific Regulation of Inflammation and Metabolic Syndrome in Obesity , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[11]  Y. Aso,et al.  Teneligliptin, a DPP-4 Inhibitor, Decreases Plasma Levels of Inflammatory Chemokines During a Standard Meal Test in Patients With Type 2 Diabetes. , 2020, The American journal of the medical sciences.

[12]  S. Rana,et al.  Oxidative stress and inflammatory markers in type 2 diabetic patients , 2020, European journal of clinical investigation.

[13]  S. Toh,et al.  Autoimmune responses and inflammation in type 2 diabetes , 2020, Journal of leukocyte biology.

[14]  Xuefeng Yu,et al.  Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions , 2020, Pharmacology & Therapeutics.

[15]  K. Ali,et al.  Levels of cytokines and GADA in type I and II diabetic patients. , 2020, Primary care diabetes.

[16]  L. G. Savchenko,et al.  Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes , 2019, Romanian journal of internal medicine = Revue roumaine de medecine interne.

[17]  T. Lehtimäki,et al.  The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients , 2019, Diabetes Care.

[18]  N. Luo,et al.  Interleukin-6 and Diabetic Retinopathy: A Systematic Review and Meta-Analysis , 2019, Current eye research.

[19]  O. Ighodaro.  Molecular pathways associated with oxidative stress in diabetes mellitus. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[20]  M. D. Turner,et al.  Type 2 diabetes - An autoinflammatory disease driven by metabolic stress. , 2018, Biochimica et biophysica acta. Molecular basis of disease.

[21]  M. Afarideh,et al.  Baseline High-Sensitivity C-Reactive Protein Predicts Macrovascular and Microvascular Complications of Type 2 Diabetes: A Population-Based Study , 2018, Annals of Nutrition and Metabolism.

[22]  A. Pérez-López,et al.  Serum IL‐15 and IL‐15Rα levels are decreased in lean and obese physically active humans , 2018, Scandinavian journal of medicine & science in sports.

[23]  T. Ota,et al.  Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization , 2017, Adipocyte.

[24]  S. Belmadani,et al.  Essential Role of IL-12 in Angiogenesis in Type 2 Diabetes. , 2017, The American journal of pathology.

[25]  Y. Duan,et al.  Interleukin‐15 in obesity and metabolic dysfunction: current understanding and future perspectives , 2017, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[26]  R. Freeman,et al.  Diabetic Neuropathy: A Position Statement by the American Diabetes Association , 2016, Diabetes Care.

[27]  Z. Andrade,et al.  Wound healing - A literature review* , 2016, Anais brasileiros de dermatologia.

[28]  J. J. Salazar,et al.  Diabetes medications: Impact on inflammation and wound healing. , 2016, Journal of diabetes and its complications.

[29]  A. Marwaha,et al.  Targeting the IL-17/IFN-γ axis as a potential new clinical therapy for type 1 diabetes. , 2014, Clinical immunology.

[30]  E. Bonifacio,et al.  Interleukin-7 and Type 1 Diabetes , 2014, Current Diabetes Reports.

[31]  Brenda,et al.  Association of Subclinical Inflammation With Polyneuropathy in the Older Population , 2013, Diabetes Care.

[32]  S. Chang.  Smoking and Type 2 Diabetes Mellitus , 2012, Diabetes & metabolism journal.

[33]  I. Sabry,et al.  Study of the role of interleukin-6 and highly sensitive C-reactive protein in diabetic nephropathy in type 1 diabetic patients. , 2012, European review for medical and pharmacological sciences.

[34]  R. Singh,et al.  Level of serum IL-12 and its correlation with endothelial dysfunction, insulin resistance, proinflammatory cytokines and lipid profile in newly diagnosed type 2 diabetes. , 2011, Diabetes research and clinical practice.

[35]  L. Baum,et al.  Independent predictive roles of eotaxin Ala23Thr, paraoxonase 2 Ser311Cys and β3‐adrenergic receptor Trp64Arg polymorphisms on cardiac disease in Type 2 Diabetes—an 8‐year prospective cohort analysis of 1297 patients , 2010, Diabetic medicine : a journal of the British Diabetic Association.

[36]  K. Makrilakis,et al.  Cytokine Secretion in Long-standing Diabetes Mellitus Type 1 and 2: Associations with Low-grade Systemic Inflammation , 2008, Journal of Clinical Immunology.

[37]  C. Richart,et al.  Lower heart rate variability is associated with higher plasma concentrations of IL-6 in type 1 diabetes. , 2007, European journal of endocrinology.

[38]  E. Wouters,et al.  Systemic effects of smoking. , 2007, Chest.

[39]  L. Bernstein,et al.  Effects of etanercept in patients with the metabolic syndrome. , 2006, Archives of internal medicine.

[40]  Harvey F Lodish,et al.  Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. , 2003, Cytokine & growth factor reviews.

[41]  Braxton D Mitchell,et al.  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. , 2003, Diabetes care.

[42]  C. Meisinger,et al.  C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. , 2003, Archives of internal medicine.

[43]  A. D. de Craen,et al.  Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes : the Leiden 85-Plus Study. , 2002, Diabetes.

[44]  J. Manson,et al.  C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.

[45]  N Rifai,et al.  Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. , 2001, JAMA.

[46]  A. Mantovani,et al.  Macrophage‐derived chemokine (MDC) , 2000, Journal of leukocyte biology.

[47]  H. Hauner,et al.  Plasma concentrations of soluble TNF-alpha receptors in obese subjects , 1998, International Journal of Obesity.

[48]  K. Uysal,et al.  Protection from obesity-induced insulin resistance in mice lacking TNF-α function , 1997, Nature.

[49]  B. Spiegelman,et al.  Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. , 1995, The Journal of clinical investigation.

[50]  Mohsen Rezaeian,et al.  Expression of CC chemokines CCL2, CCL5, and CCL11 is associated with duration of disease and complications in type-1 diabetes: a study on Iranian diabetic patients. , 2013, Clinical laboratory.

[51]  G L Viviani,et al.  Recommendations for the use of cardiovascular tests in diagnosing diabetic autonomic neuropathy. , 2011, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[52]  Peter P. Egeghy,et al.  Methods of Dealing with Values Below the Limit of Detection using SAS Carry , 2003 .